ReviewJournal of clinical hypertension (Greenwich, Conn.)2005
Pharmacotherapy review: Angiotensin receptor antagonists.
Review in Journal of clinical hypertension (Greenwich, Conn.), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations.Journal of clinical hypertension (Greenwich, Conn.) · 2007Review
- Angiotensin receptor blockers: new considerations in their mechanism of action.Journal of clinical hypertension (Greenwich, Conn.) · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiotensin receptor blockers are one of several drug classes that act by interfering with activity of the renin-angiotensin axis. Drugs in this class are as effective as angiotensin-converting enzyme inhibitors in the reduction of blood pressure in hypertensive patients. Results from a series of outcomes trials increasingly support the use of drugs in this class as cardioprotective and renoprotective agents in patients with heart failure, diabetic nephropathy, and post-myocardial infarction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.